Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407602 · ClinicalTrials.gov registry record · NA
Argus® II Retinal Stimulation System Feasibility Protocol
A NA study, sponsored by Second Sight Medical Products.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00407602: Completed NA study, sponsored by Second Sight Medical Products.
NCT00407602 is a NA study that has completed, run by Second Sight Medical Products. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00407602, a NA study, has completed, sponsored by Second Sight Medical Products.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
Investigational Phase of the Study: The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis pigmentosa. Post-Approval Phase of the Study: To collect post-approval data in order to monitor the ongoing safety and reliability of the Argus II System
Primary Outcome
Grating Visual Acuity is performed at Baseline and at various timepoints throughout the study. As of the 10 year final testing, the total number of subjects that were able to score on the logMAR scale are indicated below. The device has a scale from 1.6 to 2.9 logMAR. Maximum likelihood estimation of visual acuity is based on BEST-PEST algorithm.
Interventions
- DEVICE Implant of Argus II Retinal Prosthesis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-09 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
What the finished NCT00407602 record still lists
NCT00407602 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Implant of Argus II Retinal Prosthesis is the first listed.
NCT00407602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00407602 about?
NCT00407602 is a clinical study titled "Argus® II Retinal Stimulation System Feasibility Protocol". Investigational Phase of the Study: The objective of this feasibility study is to evaluate the safety and utility of the Argus II Retinal Stimulation System in providing visual function to blind subjects with retinitis pigmentosa. Post-Approval Phase of the Study: To collect post-approval data in...
What is the current status of trial NCT00407602?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT00407602?
The interventions under investigation include: Implant of Argus II Retinal Prosthesis (DEVICE).
Who is sponsoring clinical trial NCT00407602?
This trial is sponsored by Second Sight Medical Products, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00407602's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia